BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26782713)

  • 1. Variation in prostate cancer treatment associated with population density of the county of residence.
    Cary C; Odisho AY; Cooperberg MR
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):174-9. PubMed ID: 26782713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
    Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of early-stage prostate cancer among rural and urban patients.
    Baldwin LM; Andrilla CH; Porter MP; Rosenblatt RA; Patel S; Doescher MP
    Cancer; 2013 Aug; 119(16):3067-75. PubMed ID: 23765584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer.
    Quek RG; Master VA; Ward KC; Lin CC; Virgo KS; Portier KM; Lipscomb J
    Cancer; 2013 Oct; 119(20):3619-28. PubMed ID: 23913478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.
    Mahal BA; Aizer AA; Ziehr DR; Hyatt AS; Lago-Hernandez C; Chen YW; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Trinh QD; Nguyen PL
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):273-9. PubMed ID: 24980272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
    JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.
    Cary KC; Punnen S; Odisho AY; Litwin MS; Saigal CS; Cooperberg MR;
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):149-54. PubMed ID: 25667110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States.
    Prasad SM; Gu X; Lipsitz SR; Nguyen PL; Hu JC
    Cancer; 2012 Mar; 118(5):1260-7. PubMed ID: 21823112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic and socioeconomic variation in the treatment of prostate cancer.
    Krupski TL; Kwan L; Afifi AA; Litwin MS
    J Clin Oncol; 2005 Nov; 23(31):7881-8. PubMed ID: 16204005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors.
    Onukwugha E; Osteen P; Jayasekera J; Mullins CD; Mair CA; Hussain A
    Cancer; 2014 Nov; 120(21):3385-92. PubMed ID: 24962590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of rural residence on adult brain cancer survival in the United States.
    Delavar A; Al Jammal OM; Maguire KR; Wali AR; Pham MH
    J Neurooncol; 2019 Sep; 144(3):535-543. PubMed ID: 31385185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.
    Jacobs BL; Lopa SH; Yabes JG; Nelson JB; Barnato AE; Degenholtz HB
    Cancer; 2016 Oct; 122(20):3199-3206. PubMed ID: 27379732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
    Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
    Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.
    Aizer AA; Gu X; Chen MH; Choueiri TK; Martin NE; Efstathiou JA; Hyatt AS; Graham PL; Trinh QD; Hu JC; Nguyen PL
    J Natl Compr Canc Netw; 2015 Jan; 13(1):61-8. PubMed ID: 25583770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of receiving breast-conserving surgery. The Surveillance, Epidemiology, and End Results Program, 1983-1986.
    Samet JM; Hunt WC; Farrow DC
    Cancer; 1994 May; 73(9):2344-51. PubMed ID: 8168040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
    Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
    J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate.
    Weiner AB; Patel SG; Richards KA; Szmulewitz RZ; Eggener SE
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):286-91. PubMed ID: 25027862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and determinants of missing data in clinical and prognostic variables recently added to SEER.
    Kim HM; Goodman M; Kim BI; Ward KC
    J Registry Manag; 2011; 38(3):120-31. PubMed ID: 22223054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis.
    Hoffman KE; Hong TS; Zietman AL; Russell AH
    Cancer; 2008 Feb; 112(4):943-9. PubMed ID: 18098220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.
    Riley GF; Warren JL; Potosky AL; Klabunde CN; Harlan LC; Osswald MB
    Med Care; 2008 Oct; 46(10):1108-15. PubMed ID: 18815533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.